Abstract
INTRODUCTION The coexistence of Metabolic Syndrome in Type 2 diabetic patients significantly increases the risk of stroke and cardiovascular disease. Due to its remarkably high prevalence, metabolic syndrome has gained significant interest over the last decade. Limited information exists regarding the occurrence of Metabolic Syndrome in Type 2 diabetic patients in developing nations like Nepal. Our study aims to determine the prevalence of Metabolic Syndrome among patients with Type 2 Diabetes Mellitus in Western Nepal.
METHODS This prospective cross-sectional study was conducted at the Universal College of Medical Sciences (UCMS) among patients with Type 2 Diabetes Mellitus. Patients with gestational diabetes mellitus, Type I Diabetes Mellitus, and those aged less than 20 were excluded. Metabolic syndrome has been diagnosed based on the definition given by the International Diabetes Federation.
RESULTS The study involved 123 patients with a mean age of 61.44 ± 12.88 years, predominantly female (55.3%). Of these patients, 42.3% were classified as Obese. The overall prevalence of Metabolic Syndrome in Type 2 Diabetes Mellitus patients was 61%, comprising 75 cases. The most common component in our study was hypertension, with 82 cases (66.7%), followed by central obesity with 81 cases (65.9%). Among patients with Metabolic Syndrome, 66.7% had an estimated glomerular filtration rate (eGFR) in the 60-89 ml/min range. In females, central obesity was the most common component, while in males, hypertension was the most common component of Metabolic Syndrome.
CONCLUSION The prevalence of Metabolic Syndrome in patients with Type 2 Diabetes Mellitus was high. Therefore, timely detection and management of Metabolic Syndrome is crucial in preventing consequences and premature mortality in individuals with Type 2 Diabetes Mellitus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funders were available for this study hence, there is no role for any funder in the design and result of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Institutional Review Committee, UCMS, with letter number UCMS/IRC/134/21.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data analysis was done with the help of computer using Epidemiological Information. Using this software, frequencies, percentage, mean, standard deviation and'p' values were calculated. Data was collected, entered and analyzed in SPSS software version 17.
